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Background
Despite the advent of targeted therapies, mRCC remains
difficult to treat with limited prospect of cure. HD-IL2 is
the only agent consistently capable of achieving durable
long-term remissions. Shablak et al have previously
reported improved outcomes in patients prospectively
stratified by a pathology-based criterion compared to an
unselected population. We now present updated outcomes
of mRCC patients given first-line treatment with HD-IL2
over a 10 year period from July 2003 to July 2013.
Methods
The sample population consisted of 2 Cohorts: Cohort A
(treated July 2003 - August 2006) where patients were retro-
spectively stratified for analysis by pathology into ‘Favour-
able’ and ‘Other’ groups (’Favourable’ = < 10% papillary
features, and at least 1 of > 50% alveolar/solid, or > 50%
clear cell features); and Cohort B (treated August 2006 - July
2013) where patients were prospectively stratified. HD-IL2
was administered as per standard dosing and schedule. Clin-
ical records were reviewed retrospectively; survivals were
analysed by Kaplan-Meir methods. Carbonic Anhydrase 9
positivity (CAIX+) by immunohistochemistry was reviewed
and recorded but was not used as selection criterion.
Results
145 patients were included in the analysis. Median age 56,
72.6% male gender. Overall, 87.6% and 12.4% of patients
had ‘Favourable’ and ‘Other’ pathology type respectively.
Outcomes in patients with ‘Favourable’ histology were
consistent across all time periods with overall response
rates (ORR) and complete response (CR) rate being
41%,24%; 48%,23%; 47%,23% respectively in Cohort A,
Cohort B and the total cohort.
Median overall survival (OS) of the total cohort was
55 months. Median OS for the HD-IL2 induced CR
patients is not yet reached with 90% remaining alive and
disease-free. A further 7 patients with ‘Favourable’ pathol-
ogy achieved CR following surgical resection of residual
disease with 4 currently alive and disease-free. Those with
‘Other’ pathology clearly responded less well.
We observed a high response rate (ORR 48%, CR 26%)
in patients with CAIX+ >60%. 5 additional patients
achieving CR were captured by lowering CAIX threshold
from 80% to 60% positivity.
Conclusions
Our study confirms that HD-IL2 remains an effective first-
line treatment in well-selected patients with mRCC,
emphasising further the sustained responses and long-
term survival of those achieving a CR. Prospective applica-
tion of our pathology-based selection criterion continues
to correlate significantly with improved ORR and CR
rates. CAIX appears predictive of response even at 60%
(80% previously reported as significant), but should be
analysed further prior to being considered as a selection
adjunct.
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